TR201820051T4 - Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması - Google Patents

Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması Download PDF

Info

Publication number
TR201820051T4
TR201820051T4 TR2018/20051T TR201820051T TR201820051T4 TR 201820051 T4 TR201820051 T4 TR 201820051T4 TR 2018/20051 T TR2018/20051 T TR 2018/20051T TR 201820051 T TR201820051 T TR 201820051T TR 201820051 T4 TR201820051 T4 TR 201820051T4
Authority
TR
Turkey
Prior art keywords
factor
antibodies
prevention
treatment
thrombus formation
Prior art date
Application number
TR2018/20051T
Other languages
English (en)
Inventor
Hack Erik
Original Assignee
Prothix Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40933725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201820051(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prothix Bv filed Critical Prothix Bv
Publication of TR201820051T4 publication Critical patent/TR201820051T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Mevcut buluş, özgül olarak plazma koagülasyon faktörü XI'e bağlanan ve faktör XI aktivasyonunu ve/veya aktivitesini önleyen antikorlar gibi bağlayıcı moleküllerle ilgilidir. Buluşun faktör XI-bağlayıcı molekülleri, faktör XI aktivasyonunun aracılık ettiği hastalıkların, rahatsızlıkların ve/veya durumların engellenmesi veya tedavi edilmesi için ve/veya faktör XI'in önlenmesinin faydalı bir etkiye sahip olduğu yöntemlerde kullanılabilir.
TR2018/20051T 2008-06-19 2009-06-19 Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması TR201820051T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7388208P 2008-06-19 2008-06-19

Publications (1)

Publication Number Publication Date
TR201820051T4 true TR201820051T4 (tr) 2019-01-21

Family

ID=40933725

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/20051T TR201820051T4 (tr) 2008-06-19 2009-06-19 Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması

Country Status (9)

Country Link
US (4) US20110159006A1 (tr)
EP (1) EP2297207B1 (tr)
DK (1) DK2297207T3 (tr)
ES (1) ES2702365T3 (tr)
HR (1) HRP20181727T1 (tr)
HU (1) HUE041556T2 (tr)
PL (1) PL2297207T3 (tr)
TR (1) TR201820051T4 (tr)
WO (1) WO2009154461A1 (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160046728A1 (en) * 2007-10-31 2016-02-18 Bioxodes Sa Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands
PT3002298T (pt) 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
US8388959B2 (en) 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
WO2012105833A1 (en) * 2011-02-01 2012-08-09 Bac Ip B.V. Antigen-binding protein directed against epitope in the ch1 domain of human igg antibodies
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
EP2847228B1 (en) * 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
WO2016020880A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
HK1255041A1 (zh) * 2015-07-23 2019-08-02 The Regents Of The University Of California Fxia抑制剂的逆转剂
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
TWI736575B (zh) 2016-01-22 2021-08-21 美商默沙東藥廠 抗凝固因子ｘｉ抗體
CN109153726A (zh) * 2016-03-23 2019-01-04 普希克斯私人有限公司 抗因子xi的活性位点的单克隆抗体及其用途
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
IL263272B2 (en) 2016-06-14 2025-07-01 Merck Sharp & Dohme Antibodies to coagulation factor xi
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
US11958911B2 (en) * 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
KR20200087236A (ko) 2017-11-22 2020-07-20 노파르티스 아게 항-인자 XI/XIa 항체에 대한 반전 결합제 및 이의 용도
CA3108708A1 (en) * 2018-08-09 2020-02-13 Shanghai Benemae Pharmaceutical Corporation Anti-factor xi antibodies
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
WO1993009803A1 (en) * 1991-11-22 1993-05-27 The Scripps Research Institute Factor x-derived polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting inflammation
GB9224888D0 (en) * 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US6500660B1 (en) * 1996-11-27 2002-12-31 Université Catholique de Louvain Chimeric target molecules having a regulatable activity
WO1999001476A1 (en) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
US20030143225A1 (en) * 2001-03-08 2003-07-31 Genentech, Inc. Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
WO2003013423A2 (en) * 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
EP1433793A4 (en) * 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
CA2465891C (en) * 2001-11-05 2012-05-15 Board Of Regents, The University Of Texas System Recombinant antibodies for the detection and neutralization of anthrax toxin
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
US20040180855A1 (en) * 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
WO2005014533A2 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
CA2535489C (en) * 2003-08-14 2014-09-30 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
PT3002298T (pt) * 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
CN109153726A (zh) * 2016-03-23 2019-01-04 普希克斯私人有限公司 抗因子xi的活性位点的单克隆抗体及其用途

Also Published As

Publication number Publication date
HRP20181727T1 (hr) 2019-02-08
EP2297207A1 (en) 2011-03-23
EP2297207B1 (en) 2018-10-03
US8568724B2 (en) 2013-10-29
US20110159006A1 (en) 2011-06-30
US20180118850A1 (en) 2018-05-03
HUE041556T2 (hu) 2019-05-28
ES2702365T3 (es) 2019-02-28
DK2297207T3 (en) 2018-12-03
US20140194600A1 (en) 2014-07-10
US20120259097A1 (en) 2012-10-11
WO2009154461A1 (en) 2009-12-23
PL2297207T3 (pl) 2019-03-29

Similar Documents

Publication Publication Date Title
TR201820051T4 (tr) Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
EA200970953A1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
MX2010003095A (es) Antidotos para inhibidores del factor xa y metodos para usar los mismos.
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
EA201001865A1 (ru) Противовоспалительные агенты
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
UA98125C2 (ru) Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2011115712A3 (en) Tfpi inhibitors and methods of use
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
EP3722810A3 (en) Molecular profiling of tumors
MX385174B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
WO2010071894A3 (en) Tfpi inhibitors and methods of use
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
WO2009045356A3 (en) Microrna compositions in the treatment of vegf-mediated disorders
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
UA105487C2 (uk) Заміщені дигідропіразолони як інгібітори hif-проліл-4-гідроксилази
WO2011082245A3 (en) Metalloenzyme inhibitor compounds
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου